Patient Selection for Ciltacabtagene Autoleucel Therapy in R/R MM

Maximilian Merz

CARTITUDE-1: 2 Years Post-LPI Update on the Phase 1b/2 Study of Cilt…

UCSF School of Medicine

T. Martin

SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Mome…

SOHO Brazil 2022

M. Bishop, P. Scheinberg

Myeloma 2022: Challenges and Path Forward

UChicago Medicine

A. Jakubowiak

CAR T-Cell Therapy Side Effects for Blood Cancers

GRACE

A. Goodman

CAR-T Therapy in Myeloma: What's Here and What's Coming Soon

Rahul Banerjee

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…

SOHO 2022 Tenth Annual Meeting

T. Martin

SOHO 2022: CAR T-Cell in MM - When To Use Now, Where Are We Going?

SOHO 2022 Tenth Annual Meeting

N. S. Raje

Identifying and Managing Major Toxicities of CAR-T Therapy in Multip…

UChicago Medicine

S. Kosuri

Triple Refractory MM Patients: Learnings From the MAMMOTH and the Lo…

Enrique Ocio

CAR-T in MM: Benefits of a Treatment-Free Interval

Shaji Kumar

Summary of the MAMMOTH Trial in R/R Myeloma

Saurabh Chhabra

MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs

Zhubin Gahvari

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

ASH 2022 Conference Coverage

S. Atrash

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Indy Hematology Review

K. Anderson